Alnylam Announces Advocacy for Impact Grants to Inspire Unique Solutions that Address Unmet Needs Affecting the Rare Disease Community
− Alnylam’s Advocacy for Impact Grants Will Fund New Projects of Up
“At Alnylam we’re committed to supporting the exploration of new ideas
and believe those who represent the voice of the patient can be an
important catalyst for positive change,” said
Advocacy for Impact Grants is open to patient advocacy groups
around the world with a charitable status. The competitive grants
program will recognize and fund new projects of up to
- Increase disease awareness and access to diagnosis;
- Offer education to patients, families, caregivers, healthcare providers and/or the public; or
- Improve patient care.
Eligible patient advocacy groups must have a charitable status in their country and may only submit one proposal per year. Proposed projects may be a collaboration between two patient advocacy groups, but that is not a requirement. Patient advocacy groups may also serve multiple patient communities, but their application must be for new projects focused on the ATTR amyloidosis, acute hepatic porphyrias and/or primary hyperoxaluria type 1 communities.
Applications will be accepted online from
All applications must be submitted through the online process and include the required supporting materials. For additional information on the Advocacy for Impact Grants program and instructions on how to apply, groups can refer to the website.
Recipients of Alnylam’s Advocacy for Impact Grants will be announced in early 2019.
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference
(RNAi) into a new class of innovative medicines with the potential to
improve the lives of people afflicted with rare genetic,
cardio-metabolic, hepatic infectious, and central nervous system (CNS)
diseases. Based on Nobel Prize-winning science, RNAi therapeutics
represent a powerful, clinically validated approach for the treatment of
a wide range of severe and debilitating diseases. Founded in 2002,
Alnylam is delivering on a bold vision to turn scientific possibility
into reality, with a robust discovery platform. ONPATTRO™ (patisiran)
lipid complex injection, available in the U.S. for the treatment of the
polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis
in adults, is Alnylam’s first U.S.
Alnylam Pharmaceuticals, Inc.
(Investors and Media)
Christine Regan Lindenboom, 617-682-4340
Josh Brodsky, 617-551-8276